Pharma Base India Private Limited - Due diligence report

A 360° intelligence report on Pharmabase: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…

1998-07-14 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
PB Pharma Base India Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharmabase — 360° Intelligence Report

Generated from MCA filings & public records
80/100
Trust Score
Low Risk

Pharmabase is assessed as Low Risk with a Trust Score of 80/100. Pharmabase is an active private limited indian non-government company incorporated in 1998, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 25 Jul 2026 from the latest processed filings. Pharma Base India Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 1 satisfied (10.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Icici Bank Limited1 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (3 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DHWANI DINESH PUNAMIYA 01234567 Director 01/04/2018 6 yrs Approved
KISHOR OLIVIER PAREKH 01234567 Director 01/04/2018 6 yrs Approved
DHANANJAY THAKORBHAI DESAI 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Pharma Base Sa
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Pharma Base Sa Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 70
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Operating for 28+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
MSME payment delays disclosed - latest outstanding 52,376.00.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
03 May 2024
Director appointed
DHWANI DINESH PUNAMIYA (Company Secretary)
02 Mar 2022
Director ceased
NAMDEV DHONDU APANGE
30 Sep 2021
Director ceased
DHANANJAY THAKORBHAI DESAI
27 Oct 2020
Director ceased
PRAVINCHANDRA THAKORLAL MEHTA
01 Aug 2020
Director appointed
DHANANJAY THAKORBHAI DESAI (Director)
31 Mar 2020
Share transfer (FY 2020)
6595295.00000000 shares to Kishor Olivier Parekh
27 Sep 2019
Director ceased
KISHOR OLIVIER PAREKH
20 May 2019
Director appointed
KISHOR OLIVIER PAREKH (Director)
28 Apr 2019
Director ceased
MANOJ GUNVANTRAY OZA
Director ceased
HARISH DULERAI PAREKH
17 Apr 2015
Charge satisfied
Icici Bank Limited
22 Apr 2008
Charge created
Icici Bank Limited - 10.00 cr
25 Mar 2008
Director ceased
VIJAY RAJARAM GAWDE
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Suntec Remedies Private Limited U24232CH2014PTC035082 Chandigarh, Chandigarh, India
Ramashree Chemicals Private Limited U15332MP1987PTC004221 Bhopal, Madhya Pradesh, India
Sri Krishna Fire Works Factory Private Limited U24292TN1989PTC017073 626 123, Tamil Nadu, India
Vmk Agro Chemicals Private Limited U24210GJ2005PTC045645 Rajkot, Gujarat, India
Knowchem Laboratories Private Limited U24119PN2007PTC129702 Pune, Maharashtra, India
Khanvilkar Plasticiser Private Limited U25209MH1990PTC058996 Tarapur, Maharashtra, India
Sharp Foam Industries Private Limited U24200PN2021PTC201190 Pune City, Maharashtra, India
Curemens Vetcare Private Limited U24100KA2019PTC128892 Bangalore, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharmabase before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharmabase: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Pharmabase - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Pharmabase pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Pharmabase - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharmabase an active company?

Pharmabase has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Pharmabase financially healthy?

Pharmabase has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Pharmabase?

Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharmabase?

The ultimate holding entity is Pharma Base Sa. 3 active director(s) are on record.

Does Pharmabase have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Pharmabase up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Pharmabase?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.